Peers of Keros Therapeutics Inc (KROS)
Health Care · Biotechnology
Market capitalization divided by trailing twelve-month free cash flow.
Latest P/FCF Ratio
-4.89x
As of Oct 9, 2026
Beyond P/FCF Ratio, the valuation view includes forward multiples, EV ratios, cash flow yields, and multi-year chart history for further research.
| Date | P/FCF Ratio |
|---|---|
| Oct 9, 2026 | -4.89x |
| Oct 8, 2026 | -4.76x |
| Oct 7, 2026 | -4.58x |
| Oct 6, 2026 | -4.50x |
| Oct 5, 2026 | -4.71x |
| Oct 2, 2026 | -4.65x |
| Oct 1, 2026 | -4.60x |
| Sep 30, 2026 | -4.66x |
P/FCF Ratio = Market Capitalization / Free Cash Flow (TTM)
P/FCF focuses on actual cash generation rather than accounting profit.
Read the general P/FCF Ratio definition, formula, and analyst usage guide.
P/FCF Ratio guideInformational research only; not personalized advice. Values reflect the latest available data on Chartloom and may differ from other sources.
